Vol. 22 No. 2 (2023)
Original Articles

Insulin-like growth factor-1 short-period therapy improves Non-Alcoholic Fatty Liver Disease (NAFLD) in obese mice

pdf
  • Daniela C. Andrade,
  • Filipe Jorge Nascimento,
  • Genilza P. de Oliveira,
  • Thiago Freire,
  • Simone N. de Carvalho,
  • Ana Carolina Stumbo,
  • Laís Carvalho,
  • Alessandra A. Thole,
  • Erika Cortez
Daniela C. Andrade
Bio
Filipe Jorge Nascimento
Bio
Genilza P. de Oliveira
Bio
Thiago Freire
Bio
Simone N. de Carvalho
Bio
Ana Carolina Stumbo
Bio
Laís Carvalho
Bio
Alessandra A. Thole
Bio
Erika Cortez
Bio
DOI: https://doi.org/10.12957/bjhbs.2023.79959

Published 2023-12-20

Keywords

  • Non-Alcoholic Fatty Liver Disease,
  • Liver Fibrosis,
  • IGF-1,
  • Obesity

How to Cite

1.
Daniela C. Andrade, Nascimento FJ, P. de Oliveira G, Freire T, Simone N. de Carvalho, Ana Carolina Stumbo, Laís Carvalho, Alessandra A. Thole, Erika Cortez. Insulin-like growth factor-1 short-period therapy improves Non-Alcoholic Fatty Liver Disease (NAFLD) in obese mice. BJHBS [Internet]. 2023 Dec. 20 [cited 2025 Jan. 22];22(2). Available from: https://bjhbs.hupe.uerj.br/bjhbs/article/view/151

Copyright (c) 2023 Brazilian Journal of Health and Biomedical Sciences

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Crossref
Scopus
Google Scholar
Europe PMC

Abstract

This study seeks to evaluate Insulin-like Growth Factor 1 (IGF-1) short-period therapy in Non-Alcoholic Fatty Liver Disease (NAFLD) as it relates to western diet-induced obesity. For this purpose, 21-day-old male Swiss mice were divided into a control group (CG, N=8), which was fed a standard diet, and an obese group (GO, N=16), which was fed a western diet, rich in saturated fat and simple carbohydrates, for 12 weeks. In the 11th week, part of the animals in the obese group (N=8) received a daily subcutaneous injection of recombinant human IGF-1 (100µg/kg/day) during seven consecutive days (GO+IGF-1). Biometric and metabolic parameters, intraperitoneal glucose tolerance test (IGTT), quantitative analysis of liver steatosis, quantitative analysis of collagen in liver and expression of immunoperoxidase of alpha-smooth muscle actin (a-SMA) were analyzed. Our data demonstrated that IGF-1 short-term treatment was able to improve obesity-related biometric and metabolic parameters. In addition, it promoted the recovery of liver parenchyma, thereby reducing steatosis and fibrosis, thus demonstrating an important hepatoprotective action. 

pdf

Metrics

Metrics Loading ...

References

  1. Popkin BM. Contemporary nutritional transition: determinants of diet and its impact on body composition. Proc Nutr Soc. 2011 Feb;70(1):82-91. doi: 10.1017/S0029665110003903. Epub 2010 Nov 22. PMID: 21092363; PMCID: PMC3029493.
  2. Tikellis C, Thomas MC, Harcourt BE, et al. Cardiac inflammation associated with a Western diet is mediated via activation of RAGE by AGEs. Am J Physiol Endocrinol Metab. 2008 Aug;295(2):E323-30. doi: 10.1152/ajpendo.00024.2008. Epub 2008 May 13. PMID: 18477705; PMCID: PMC2652498.
  3. Global BMIMC, Di Angelantonio E, Bhupathiraju Sh N, et al. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. Lancet 2016;388:776–86.
  4. Marques V, Afonso MB, Bierig N, et al. Adiponectin, Leptin, and IGF-1 are useful diagnostic and stratification biomarkers of NAFLD. Front Med (Lausanne). 2021 Jun 23;8:683250. doi: 10.3389/fmed.2021.683250. PMID: 34249975; PMCID: PMC8260936.
  5. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases.
  6. Sheka AC, Adeyi O, Thompson J, et al. Nonalcoholic Steatohepatitis: A Review. JAMA. 2020 Mar 24;323(12):1175-1183. doi: 10.1001/jama.2020.2298. Erratum in: JAMA. 2020 Apr 28;323(16):1619. PMID: 32207804.
  7. Wang DQ, Portincasa P, Neuschwander-Tetri BA. Steatosis in the liver. Compr Physiol. 2013 Oct;3(4):1493-532. doi: 10.1002/cphy.c130001. PMID: 24265237.
  8. Berryman DE, Glad CA, List EO, et al. The GH/IGF-1 axis in obesity: pathophysiology and therapeutic considerations. Nat Rev Endocrinol. 2013 Jun;9(6):346-56. doi: 10.1038/nrendo.2013.64. Epub 2013 Apr 9. PMID: 23568441.
  9. Ren J, Anversa P. The insulin-like growth factor I system: physiological and pathophysiological implication in cardiovascular diseases associated with metabolic syndrome. Biochem Pharmacol. 2015 Feb 15;93(4):409-17. doi: 10.1016/j.bcp.2014.12.006. Epub 2014 Dec 23. PMID: 25541285.
  10. Arturi F, Succurro E, Procopio C, et al. Nonalcoholic fatty liver disease is associated with low circulating levels of insulin-like growth factor-I. J Clin Endocrinol Metab. 2011 Oct;96(10):E1640-4. doi: 10.1210/jc.2011-1227. Epub 2011 Aug 3. PMID: 21816784.
  11. Andrade D, Oliveira G, Menezes L, et al. Insulin-like growth factor-1 short-period therapy improves cardiomyopathy stimulating cardiac progenitor cells survival in obese mice. Nutr Metab Cardiovasc Dis. 2020 Jan 3;30(1):151-161. doi: 10.1016/j.numecd.2019.09.001. Epub 2019 Sep 9. PMID: 31753790.
  12. de Oliveira GP, de Andrade DC, Nascimento ALR. Insulin-like growth factor-1 short-period therapy stimulates bone marrow cells in obese Swiss mice. Cell Tissue Res. 2021 Jun;384(3):721-734. doi: 10.1007/s00441-020-03357-9. Epub 2021 May 11. PMID: 33977324.
  13. Vitale G, Pellegrino G, Vollery M, et al. ROLE of IGF-1 System in the modulation of longevity: controversies and new insights from a centenarians' perspective. Front Endocrinol (Lausanne). 2019 Feb 1;10:27. doi: 10.3389/fendo.2019.00027. PMID: 30774624; PMCID: PMC6367275.
  14. Liu JL. Does IGF-I stimulate pancreatic islet cell growth? Cell Biochem Biophys. 2007;48(2-3):115-25. doi: 10.1007/s12013-007-0016-7. PMID: 17709881.
  15. Takahashi Y, Soejima Y, Fukusato T. Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol. 2012;18(19):2300-2308. https://doi.org/10.3748/wjg.v18.i19.2300
  16. Nishizawa H, Takahashi M, Fukuoka H, et al. GH-independent IGF-I action is essential to prevent the development of nonalcoholic steatohepatitis in a GH-deficient rat model. Biochem Biophys Res Commun. 2012 Jun 29;423(2):295-300. doi: 10.1016/j.bbrc.2012.05.115. Epub 2012 May 30. PMID: 22659415.
  17. Del Campo JA, Gallego P, Grande L. Role of inflammatory response in liver diseases: Therapeutic strategies. World J Hepatol. 2018 Jan 27;10(1):1-7. doi: 10.4254/wjh.v10.i1.1. PMID: 29399273; PMCID: PMC5787673.
  18. Heyens LJM, Busschots D, Koek GH, et al. Liver fibrosis in non-alcoholic fatty liver disease: from liver biopsy to non-invasive biomarkers in diagnosis and treatment. Front Med (Lausanne). 2021 Apr 14;8:615978. doi: 10.3389/fmed.2021.615978. PMID: 33937277; PMCID: PMC8079659.
  19. Wahid B, Ali A, Rafique S, et al. Role of altered immune cells in liver diseases: a review. Gastroenterol Hepatol. 2018 Jun-Jul;41(6):377-388. English, Spanish. doi: 10.1016/j.gastrohep.2018.01.014. Epub 2018 Mar 28. PMID: 29605453.
  20. Weiskirchen R, Weiskirchen S, Tacke F. Recent advances in understanding liver fibrosis: bridging basic science and individualized treatment concepts. F1000Res. 2018 Jun 27;7:F1000 Faculty Rev-921. doi: 10.12688/f1000research.14841.1. PMID: 30002817; PMCID: PMC6024236.
  21. Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016 Aug;65(8):1038-48. doi: 10.1016/j.metabol.2015.12.012. Epub 2016 Jan 4. PMID: 26823198.
  22. Higashi T, Friedman SL, Hoshida Y. Hepatic stellate cells as key target in liver fibrosis. Adv Drug Deliv Rev. 2017 Nov 1;121:27-42. doi: 10.1016/j.addr.2017.05.007. Epub 2017 May 12. PMID: 28506744; PMCID: PMC5682243.
  23. Ramzy MM, Abdelghany HM, Zenhom NM, et al. Effect of histone deacetylase inhibitor on epithelial-mesenchymal transition of liver fibrosis. IUBMB Life. 2018 Jun;70(6):511-518. doi: 10.1002/iub.1742. Epub 2018 Mar 30. PMID: 29601129.
  24. Yoshiji H, Kuriyama S, Miyamoto Y, et al. Tissue inhibitor of metalloproteinases-1 promotes liver fibrosis development in a transgenic mouse model. Hepatology. 2000 Dec;32(6):1248-54. doi: 10.1053/jhep.2000.20521. PMID: 11093731.
  25. Roeb E, Purucker E, Breuer B, et al. TIMP expression in toxic and cholestatic liver injury in rat. J Hepatol. 1997 Sep;27(3):535-44. doi: 10.1016/s0168-8278(97)80359-5. PMID: 9314132.
  26. Soleimani D, Ranjbar G, Rezvani R, et al. Dietary patterns in relation to hepatic fibrosis among patients with nonalcoholic fatty liver disease. Diabetes Metab Syndr Obes. 2019 Mar 12;12:315-324. doi: 10.2147/DMSO.S198744. PMID: 30881075; PMCID: PMC6420105.
  27. Hribal ML, Procopio T, Petta S, et al. Insulin-like growth factor-I, inflammatory proteins, and fibrosis in subjects with nonalcoholic fatty liver disease. J Clin Endocrinol Metab. 2013 Feb;98(2):E304-8. doi: 10.1210/jc.2012-3290. Epub 2013 Jan 11. PMID: 23316084.
  28. Luo X, Jiang X, Li J, et al. Insulin-like growth factor-1 attenuates oxidative stress-induced hepatocyte premature senescence in liver fibrogenesis via regulating nuclear p53-progerin interaction. Cell Death Dis. 2019 Jun 6;10(6):451. doi: 10.1038/s41419-019-1670-6. PMID: 31171766; PMCID: PMC6554350.
  29. Nishizawa H, Iguchi G, Fukuoka H, et al. IGF-I induces senescence of hepatic stellate cells and limits fibrosis in a p53-dependent manner. Sci Rep. 2016 Oct 10;6:34605. doi: 10.1038/srep34605. PMID: 27721459; PMCID: PMC5056388.
  30. Sanz S, Pucilowska JB, Liu S, et al. Expression of insulin-like growth factor I by activated hepatic stellate cells reduces fibrogenesis and enhances regeneration after liver injury. Gut. 2005 Jan;54(1):134-41. doi: 10.1136/gut.2003.024505. PMID: 15591519; PMCID: PMC1774353.

Most read articles by the same author(s)